Evaluation of a recombinant human gelatin as a substitute for a hydrolyzed porcine gelatin in a refrigerator-stable Oka/Merck live varicella vaccine.
Level 5 - mechanism / opinion, no new human data
Laboratory formulation and stability study with no human data (Oxford CEBM Level 5).
PubMed 17319952 · doi:10.1186/1476-8518-5-4
What was done
Researchers evaluated an 8.5 kD recombinant human gelatin fragment as a substitute for hydrolyzed porcine gelatin in experimental live, attenuated varicella-zoster virus (Oka/Merck) vaccine formulations. Viral harvests were prepared using each gelatin type and compared for viral potency retention during lyophilization, as well as viral stability during storage under accelerated and real-time temperature conditions.
What was found
The recombinant human gelatin provided viral potency stabilization during lyophilization comparable to that achieved with porcine gelatin. Across all tested storage temperatures, no statistically significant difference in viral potency stability was observed between the two formulations. The abstract reports no specific numerical potency values, storage temperatures, durations, or p-values.
Why it matters
Demonstrates the laboratory feasibility of replacing animal-derived gelatin in live varicella vaccine formulations with a recombinant human gelatin fragment to maintain refrigerator stability without porcine excipients.
Limits
This was an in vitro formulation study; no safety, reactogenicity, or immunogenicity testing in animals or humans was reported. The abstract provides purely qualitative statements with no raw numbers, sample sizes, shelf-life durations, or statistical confidence intervals.
Cited by
- supports Gelatin used as a stabilizer in some vaccines is derived from pigs.